Boston Scientific’s Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options. Particularly ...

Boston Scientific Corporation BSX recently closed ... well owing to the strong performances of Rezum and SpaceOAR. The Endoscopy business is also gaining from strong worldwide demand for its ...

Boston Scientific closes the year at historic highs, with investors refusing to liquidate even at these levels. Check out why ...

Boston Scientific Corporation BSX remains in the spotlight, with its stock currently trading close to its 52-week high. In the past six trading sessions, the stock has consistently traded above $90.00 ...

Disclosure: David Carr-Locke, MD, FRCP, has disclosed that he has received grants for clinical research from Boston Scientific Endoscopy, ConMed Endoscopy, Bard, Inscope, and Oridion. Dr. Carr ...

Boston Scientific Corp. engages in the development ... The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral ...

Dr. Carr-Locke has also disclosed that he has received grants for clinical research from Boston Scientific Endoscopy and CONMED.

The latest rate cuts should help Boston Scientific expand in MedTech's most attractive markets like Cardiovascular, Endoscopy, Urology and Neuromodulation by speeding up and scaling up its ...